The polyclonal activation of T cells in the periphery induced by anti-CTLA-4 was however shown to correlate with treatment-related auto-immune toxicity rather than with tumor response in both preclinical models [33] and human studies [59, 61]. This evidence concerns the gene CTLA4 and neoplasm.